Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24721469 | 0.98 | MAPT (0.35) | MAPTSMN1; SMN2 | |
| SCHEMBL23601769 | 0.92 | MAPT (0.34) | MAPTSMN1; SMN2 | |
| SCHEMBL23601755 | 0.90 | MAPT (0.36) | MAPTSMN1; SMN2 | |
| SCHEMBL23601454 | 0.87 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL23601888 | 0.87 | MAPT (0.32) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL24721474 | 0.86 | MAPT (0.33) | MAPTSMN1; SMN2 | |
| SCHEMBL23601483 | 0.86 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL23601455 | 0.85 | — | — | |
| SCHEMBL23601744 | 0.85 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL23601774 | 0.84 | MAPT (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4206/4885SMN1; SMN2 4737/4885KDM4E 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.